CHF1.5 million for making proton therapy safer and faster

Compared to conventional radiotherapy with x-rays, proton therapy has the advantage that healthy tissue surrounding the tumor receives less dose. Terapet develops innovative solutions to make this cancer treatment even more safe, precise and fast. The Geneva-based medtech start-up has been awarded of a total of about CHF 1’530’000 non-dilutive funds.

The combined funding supports the development of Terapet’s first full-scale prototype to be installed for clinical validation and for building two strong consortia between Terapet and world class research institutes: one with CERN, funded through an Innosuisse Innovation Project, and one with Karolinska Institute and the first Nordic Proton Therapy facility, Skandion Clinic, funded through the Eurostars Program.

Both research and development collaborations will officially start on 01.02.2021 and last for the coming 3 years. All the research parties in the consortium are fully funded. The European project is funded with EUR 700’000 through Eurostars Program and the project with CERN with about CHF 750’000 by Innosuisse. Innosuisse has been supporting Terapet since the very start of the project including Start-up training courses, Initial Coach Program, Core Coach Program, Mentoring as well as the Innosuisse Innovation Cheque for the initial collaboration with CERN.